Risk factors

What the long term data tells us about evolocumab in FH

A long-term follow-up of evolocumab in patients with familial hypercholesterolemia (FH) has found the PCSK9 inhibitor is well tolerated and effective in reducing LDL-C levels. The open-label single-arm study comprised 300 patients as young as 12 years with either homozygous or severe heterozygous FH and receiving stable lipid lowering therapy including statins and ezetimibe in ...

Already a member?

Login to keep reading.

© 2021 the limbic